ArticleBritish journal of cancer2013

First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer.

D Bianchini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.